Efficacy of Nebulized Lidocaine, Salbutamol, and Beclomethasone Plus Salbutamol in the Covid-19 Patients With ARDS on Non-invasive Ventilation; Randomized Control Trial

Sheikh Zayed Medical College

Status and phase: Unknown; Phase 1

Conditions: COVID-19 Acute Respiratory Distress Syndrome

Treatments: Drug: Lidocaine

Study type: Interventional

Funder types: Other

Identifiers

NCT04979923

227/IRB/SZMC/SZH

Details and patient eligibility

About

The COVID-19, a pandemic as declare by WHO1, has a devastating impact on health and economic worldwide2. Literature suggests that acute respiratory distress syndrome (ARDS) develops over 20% of the infected individuals with Coivd-pneumonia3 along with other symptoms like fever followed by cough and dyspnea as well as chest pain in severe cases4. The current preventative strategies are non-specific10, and current interventions are predominantly supportive1. Recently, some studies have demonstrated anti-inflammatory actions for local anesthetics including lidocaine.

Enrollment: 81 estimated patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Covid-19 positive
• Moderate to severe ARDS

Exclusion criteria

• patients with COPD or taking bronchodilators and steroids for chronic respiratory illnesses

Trial design

Primary purpose: Supportive Care

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

81 participants in 3 patient groups, including a placebo group

Lidocaine group

Experimental group

Treatment:

Drug: Lidocaine

Salbutamol group

Placebo Comparator group

Treatment:

Drug: Lidocaine

Beclomethasone plus salbutamol

Active Comparator group

Treatment:

Drug: Lidocaine